TY - ABST
T1 - Prediction of liver fat in people with and without type 2 diabetes: an IMI DIRECT study
AU - Pasdar, N. Atabaki
AU - Ohlsson, M.
AU - Vinuela, A.
AU - Frau, F.
AU - Koivula, R.
AU - Fernández, J
AU - Thomas, E.
AU - Mari, A.
AU - Gupta, R.
AU - Kurbasic, A.
AU - Pearson, E.
AU - Pavo, I.
AU - Bell, J.
AU - Franks, Paul W.
PY - 2018
Y1 - 2018
N2 - Background and aims: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and causes serious health complications in type 2 diabetes (T2D) and beyond. In NAFLD, triglycerides accumulate in hepatocytes, promoting hepatic gluconeogenesis, and thereby raising risk of T2D or exacerbating the disease pathology. Liver biopsy, MRI scans, ultrasounds and liver enzyme tests are often used for NAFLD diagnosis, but the invasive nature of biopsies, the high costs of the MRI scans and ultrasounds and the low accuracy of liver enzyme tests are significant limitations. Here, we aim to derive a prediction tool for NAFLD by applying machine learning approaches to the extensive phenotypic data obtained in participants with pre-diabetes or diabetes cohorts from IMI DIRECT.
AB - Background and aims: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and causes serious health complications in type 2 diabetes (T2D) and beyond. In NAFLD, triglycerides accumulate in hepatocytes, promoting hepatic gluconeogenesis, and thereby raising risk of T2D or exacerbating the disease pathology. Liver biopsy, MRI scans, ultrasounds and liver enzyme tests are often used for NAFLD diagnosis, but the invasive nature of biopsies, the high costs of the MRI scans and ultrasounds and the low accuracy of liver enzyme tests are significant limitations. Here, we aim to derive a prediction tool for NAFLD by applying machine learning approaches to the extensive phenotypic data obtained in participants with pre-diabetes or diabetes cohorts from IMI DIRECT.
U2 - 10.1007/s00125-018-4693-0
DO - 10.1007/s00125-018-4693-0
M3 - Conference abstract in journal
C2 - 30132038
SN - 0012-186X
VL - 61
SP - S581
JO - Diabetologia
JF - Diabetologia
IS - 1S
M1 - 1189
ER -
